Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 112-117

  Op den Kamp, C M ^a   Langen, R C ^a   Minnaard, R ^a   Kelders, M C ^a   Snepvangers, F J ^a   Hesselink, M K ^a   Dingemans, A C ^a   Schols, A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cachexia; Cancer; Exercise capacity; Inflammation; NF B; Non small cell lung cancer; Pre cachexia; Skeletal muscle; Ubiquitin proteasome system; VO 2 max

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUSCLE PROTEIN; PROTEASOME; TUMOR NECROSIS FACTOR RECEPTOR; UBIQUITIN;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY MASS; CACHEXIA; CANCER STAGING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DETERIORATION; EXERCISE; FEMALE; FIBRINOGEN BLOOD LEVEL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE MASS; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; SKELETAL MUSCLE; SMOKING; VASTUS LATERALIS MUSCLE; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; C-REACTIVE PROTEIN; CACHEXIA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RESPIRATORY FUNCTION TESTS; SIGNAL TRANSDUCTION; UBIQUITIN; WEIGHT LOSS;

EID: 84858003660     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.012     Document Type: Article

References (29)

1. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12:489-495.
2. Ross P.J., Ashley S., Norton A., Priest K., Waters J.S., Eisen T., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 2004, 90:1905-1911.
3. Tisdale M.J. Cachexia in cancer patients. Nat Rev Cancer 2002, 2:862-871.
4. Tan B.H., Fearon K.C. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008, 11:400-407.
5. von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle 2010, 1:1-5.
6. Bossola M., Pacelli F., Tortorelli A., Doglietto G.B. Cancer cachexia: it's time for more clinical trials. Ann Surg Oncol 2007, 14:276-285.
7. Fong Y., Moldawer L.L., Marano M., Wei H., Barber A., Manogue K., et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989, 256:R659-R665.
8. Argiles J.M., Busquets S., Lopez-Soriano F.J. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 2005, 37:2036-2046.
9. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
10. Camps C., Iranzo V., Bremnes R.M., Sirera R. Anorexia-cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Support Care Cancer 2006, 14:1173-1183.
11. Ciechanover A., Iwai K. The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 2004, 56:193-201.
12. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
13. Tanoue L.T., Detterbeck F.C. New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther 2009, 9:413-423.
14. Mazess R.B., Barden H.S., Bisek J.P., Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990, 51:1106-1112.
15. Jones N.L., Makrides L., Hitchcock C., Chypchar T., McCartney N. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 1985, 131:700-708.
16. Gosker H.R., Lencer N.H., Franssen F.M., van der Vusse G.J., Wouters E.F., Schols A.M., et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest 2003, 123:1416-1424.
17. Plasqui G., Joosen A.M., Kester A.D., Goris A.H., Westerterp K.R. Measuring free-living energy expenditure and physical activity with triaxial accelerometry. Obes Res 2005, 13:1363-1369.
18. Leeuwenberg J.F., Dentener M.A., Buurman W.A. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol 1994, 152:5070-5076.
19. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 1975, 35:609-616.
20. Hobler S.C., Williams A., Fischer D., Wang J.J., Sun X., Fischer J.E., et al. Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis. Am J Physiol 1999, 277:R434-R440.
21. Minnaard R., Wagenmakers A.J., Combaret L., Attaix D., Drost M.R., van Kranenburg G.P., et al. Ubiquitin-proteasome-dependent proteolytic activity remains elevated after zymosan-induced sepsis in rats while muscle mass recovers. Int J Biochem Cell Biol 2005, 37:2217-2225.
22. Williams A., Sun X., Fischer J.E., Hasselgren P.O. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999, 126:744-749.
23. Khal J., Hine A.V., Fearon K.C., Dejong C.H., Tisdale M.J. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005, 37:2196-2206.
24. Smith I.J., Aversa Z., Hasselgren P.O., Pacelli F., Rosa F., Doglietto G.B., et al. Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. Muscle Nerve 2011, 43(3):410-414.
25. Jagoe R.T., Redfern C.P., Roberts R.G., Gibson G.J., Goodship Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin Sci (Lond) 2002, 102:353-361.
26. Bobbio A., Chetta A., Internullo E., Ampollini L., Carbognani P., Bettati S., et al. Exercise capacity assessment in patients undergoing lung resection. Eur J Cardiothorac Surg 2009, 35:419-422.
27. Jones L.W., Watson D., Herndon J.E., Eves N.D., Haithcock B.E., Loewen G., et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer 2010, 116:4825-4832.
28. Broekhuizen R., Wouters E.F., Creutzberg E.C., Schols A.M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22.
29. Yende S., Waterer G.W., Tolley E.A., Newman A.B., Bauer D.C., Taaffe D.R., et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61:10-16.